Viral-Mediated Gene Replacement Therapy in the Developing Central Nervous System: Current Status and Future...

Area of Science:

• Neuroscience
• Genetics
• Biotechnology

Background:

• Pediatric central nervous system (CNS) neurogenetic disorders represent a significant unmet medical need.
• Viral-mediated gene replacement therapy (VGMT) has emerged as a promising therapeutic strategy for these conditions.

Purpose of the Study:

• To provide a comprehensive overview of recent advancements in VGMT for pediatric CNS neurogenetic disorders.
• To highlight emerging trends and challenges in the development and application of VGMT.

Main Methods:

• Review of current viral vector platforms including adenovirus, adeno-associated virus, lentivirus/retrovirus, and herpes simplex virus type 1.
• Analysis of studies investigating these platforms in cell cultures and animal models.
• Overview of VGMT clinical trials for various pediatric neurogenetic disorders.

Main Results:

• Several viral platforms are under investigation for VGMT in pediatric neurogenetic disorders.
• VGMT has been applied in clinical trials for conditions such as Canavan disease, spinal muscular atrophy, and others.
• Spinal muscular atrophy is the only condition with an approved VGMT.

Conclusions:

• Significant progress has been made in VGMT for pediatric CNS neurogenetic disorders.
• Numerous challenges remain in optimizing viral vector delivery and efficacy.
• Overcoming these challenges is crucial for advancing VGMT in this field.